RDH13: Potential Drug Target Or Biomarker for Eye Diseases (G112724)

Target Name: RDH13

NCBI ID: G112724

RDH13

RDH13: Potential Drug Target Or Biomarker for Eye Diseases

RDH13 (RDH13 variant 1) is a gene that encodes for a protein known as retinal dehydration hedgehog (RDH) 13. RDH proteins are a family of transmembrane proteins that are involved in the regulation of cell signaling pathways, including the Wnt/FGF signaling pathway. This pathway plays a crucial role in the development and maintenance of tissues, including the retina.

RDH13 is a variant of the RDH gene that has been identified as a potential drug target or biomarker. The RDH gene is known to be involved in the development and maintenance of the retina, and studies have suggested that changes in the levels or activity of RDH proteins may contribute to the development of various eye diseases, including age-related macular degeneration (AMD), cataracts, and glaucoma.

The Wnt/FGF signaling pathway is a critical pathway that is involved in the development and maintenance of tissues, including the retina. This pathway is known to be activated in response to the presence of Wnt, a protein that is found in the lens of the eye. Wnt signaling is involved in the regulation of cell proliferation, differentiation, and survival, and is thought to play a role in the development of various eye diseases.

Studies have suggested that changes in the levels or activity of RDH proteins may contribute to the development of AMD, cataracts, and glaucoma. For example, studies have shown that the levels of RDH13 protein are decreased in the retina of individuals with age-related macular degeneration (AMD), and that this decrease is associated with the development of AMD-like changes in the retina.

In addition, studies have also shown that changes in the levels or activity of RDH13 protein are associated with the development of cataracts and glaucoma. For example, research has shown that individuals with certain genetic variations in the RDH gene, including the variant that is associated with RDH13, are at increased risk of developing cataracts.

The RDH gene has also been implicated in the development of other eye diseases, including uveal cancer and neurodegenerative diseases. For example, studies have shown that individuals with certain genetic variations in the RDH gene are at increased risk of developing uveal cancer, a type of eye cancer.

Given the involvement of the Wnt/FGF signaling pathway in the development and maintenance of tissues, as well as the association of changes in the levels or activity of RDH13 protein with the development of eye diseases, it is possible that RDH13 could be a drug target or biomarker. Further research is needed to determine the exact role of RDH13 in the development and maintenance of tissues, and to explore the potential clinical applications of targeting this gene.

Protein Name: Retinol Dehydrogenase 13

Functions: Retinol dehydrogenase with a clear preference for NADP. Oxidizes all-trans-retinol, but seems to reduce all-trans-retinal with much higher efficiency (PubMed:18039331). Has no activity toward steroids (PubMed:18039331)

The "RDH13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RDH13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets